Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Clinical trial NCT05802225 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05802225
- Sponsor
- Biocad
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-30
- Primary completion
- 2025-06-06
- Enrollment
- 398
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.